Sg Americas Securities, LLC Affimed N.V. Transaction History

Sg Americas Securities, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 28, 2023	BUY	$0.66 - $1.29 $31,165 - $60,915	47,221 Added 228.29%	67,906 $51,000
Q4 2022 Feb 02, 2023	SELL	$1.1 - $2.45 $26,083 - $58,094	-23,712 Reduced 53.41%	20,685 $26,000
Q3 2022 Oct 31, 2022	BUY	$1.96 - $3.32 $87,018 - $147,398	44,397 New	44,397 $91,000
Q1 2022 Apr 29, 2022	SELL	$3.69 - $5.65 $57,191 - $87,569	-15,499 Closed	0 $0
Q4 2021 Feb 07, 2022	SELL	$5.37 - $7.07 $212,614 - $279,922	-39,593 Reduced 71.87%	15,499 $86,000
Q3 2021 Nov 01, 2021	BUY	$5.54 - $7.51 $305,209 - $413,740	55,092 New	55,092 $340,000
Q2 2021 Aug 12, 2021	SELL	$7.78 - $11.4 $170,444 - $249,751	-21,908 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$5.12 - $8.48 $112,168 - $185,779	21,908 New	21,908 $173,000
Q3 2020 Nov 09, 2020	SELL	$3.26 - $4.73 $131,241 - $190,420	-40,258 Closed	0 $0
Q2 2020 Jul 20, 2020	BUY	$1.58 - $4.63 $15,585 - $45,670	9,864 Added 32.45%	40,258 $186,000
Q1 2020 Apr 30, 2020	BUY	$1.44 - $3.02 $43,767 - $91,789	30,394 New	30,394 $48,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg Americas Securities, LLC with notifications on news.